Effect of Proton Pump Inhibitors (pantoprazol) on Hypomagnesaemia

Impact of Proton Pump Inhibitors (pantoprazol) on Arrhythmia and Hypomagnesaemia Following off pump CABG

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201511088384N5

Enrollment

380

Registered

2016-07-17

Start date

2016-08-31

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerotic heart disease. Coronary (artery): atheroma atherosclerosis disease sclerosis

Interventions

Intervention 1: Ranitidine 50 mg three times a day intravenously on days of hospitalization in ICU and NPO and famotidine 40 mg tablet once a day orally during hospitalization in ICU (PO patient), and

Treatment - Drugs

Ranitidine 50 mg three times a day intravenously on days of hospitalization in ICU and NPO and famotidine 40 mg tablet once a day orally during hospitalization in ICU (PO patient), and cardiac surgery

Pantoprazole 40 mg twice a day intravenously when they are stay in the ICU and NPO. And 40 mg once a day orally during hospitalization in ICU (PO patient) and cardiac surgery (POST-ICU).

Eligibility

Sex/Gender

All

Age

6 Years to No maximum

Inclusion criteria

Inclusion criteria: ??????? ?????? ????? CABG ?? ??? off-pump ???? ?????? ?????? ??. ???????? ???? ?? ?????? ???? ??? ????? ?? ????: ??? ????? ?????? ??????? ??? ????? ????? ???? ??? ??????? ???????? ?? ?? ?? ????? ??? ????? CABG ?? ??? on-pump ???? ???????? ????? ?????? ?????? ??? ???? ???? ???????? ??? ????????? ??????? ???? ? ?? ??????? single kidney? ?????? ?? ???? ???? ???? ??? ? CPR ?????? ??? ???? ?????CABG ???????? ??????? ????? ?? ??? ????? ????? ????? ?????? ?? ??????? ???? ??????? ? ?? ???? ????? ?????? ?????? ?? ??????? ?? ????? ??????? ????? ?? ??????? ???? ?? EF< 35%? ???? ?????? ?????? ???? ??? ???? ????? ???? ??????? ?? ??????? ????? CABG ????? ????? ?????? ?????????? ( ???? ?? ???? ?????/ ????? ) ??? ?? ???? ??????? ??????? ?? ???? ?????? ?????? ????? ????? QT ??????? QT ?????? ??????? ? ????? ??????? ?? ????? ??????? ???? ? ??? ????? ?? ?????????? ? H2 ?????.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Hypomagnesaemia. Timepoint: Before/ after surgery. Method of measurement: serum.	—

Secondary

Measure	Time frame
Arrhythmia. Timepoint: After surgery. Method of measurement: ECG.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHassan Abbaspour

Mashhad University of Medical Sciences

Abbaspourh931@mums.ac.ir+98 51 3603 6380

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026